about
Development and Validation of an HIV Risk Exposure and Indicator Conditions Questionnaire to Support Targeted HIV Screening.Dutrebis (lamivudine and raltegravir) for use in combination with other antiretroviral products for the treatment of HIV-1 infection.Virological response to short-course maraviroc monotherapy does not predict viral tropism in HIV-1-infected treatment-naive patients.Changes in Kidney Function and in the Rate of Tubular Dysfunction After Tenofovir Withdrawal or Continuation in HIV-Infected Patients.Bone mineral density decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected patients.The influence of patient beliefs and treatment satisfaction on the discontinuation of current first-line antiretroviral regimens.Incidence and prognosis of immune reconstitution inflammatory syndrome in HIV-associated progressive multifocal leucoencephalopathy.Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis.Prevalence and significance of proximal renal tubular abnormalities in HIV-infected patients receiving tenofovir.Delayed liver fibrosis in HTLV-2-infected patients co-infected with HIV-1 and hepatitis C virus with suppressive antiretroviral therapy.Efficacy and pharmacokinetics of the combination of etravirine plus raltegravir as novel dual antiretroviral maintenance regimen in HIV-infected patients.Effect of a monthly dose of calcidiol in improving vitamin D deficiency and secondary hyperparathyroidism in HIV-infected patients.High levels of CD4⁺ CTLA-4⁺ Treg cells and CCR5 density in HIV-1-infected patients with visceral leishmaniasis.Prevalence of insulin resistance and risk of diabetes mellitus in HIV-infected patients receiving current antiretroviral drugs.Central nervous system antiretroviral penetration and cognitive functioning in largely pretreated HIV-infected patients.Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C).[Potential role of rilpivirine in simplification regimens].Efficacy of dual therapy with lamivudine plus darunavir boosted with ritonavir once daily in HIV-infected patients with nucleoside analogue toxicity.[Consensus statement: recommendations for the management of metabolic bone disease in human immunodeficiency virus patients].Sexualized Drug Use (Chemsex) Is Associated with High-Risk Sexual Behaviors and Sexually Transmitted Infections in HIV-Positive Men Who Have Sex with Men: Data from the U-SEX GESIDA 9416 Study.Dolutegravir and rilpivirine for the maintenance treatment of virologically suppressed HIV-1 infection.Increased prevalence of asymptomatic vertebral fractures in HIV-infected patients over 50 years of ageSwitching to abacavir versus use of a nucleoside-sparing dual regimen for HIV-infected patients with tenofovir-associated renal toxicityEffectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL studyMaintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patientsRisk, Diagnostic and Predictor Factors for Classical Hodgkin Lymphoma in HIV-1-Infected Individuals: Role of Plasma Exosome-Derived miR-20a and miR-21Long-term improvement in renal, bone, lipid parameters, and CD4/CD8 ratio in HIV-infected patients switching to a dual therapy with lamivudine plus boosted darunavirLack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapyDolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical settingEvaluation of kidney function in HIV-infected patients receiving an antiretroviral regimen containing one or two inhibitors of the tubular secretion of creatinineSwitching to dual antiretroviral regimens is associated with improvement or no changes in activation and inflammation markers in virologically suppressed HIV-1-infected patients: the TRILOBITHE pilot studyImpact of a structured HIV testing program in a hospital emergency department and a primary care centerCD4/CD8 ratio improvement in HIV-1-infected patients receiving dual antiretroviral treatment
P50
Q36566827-53FE4163-5081-4C76-B387-835488168BAAQ38620257-50B0BC65-57F8-4597-9791-5D6D019E0CCDQ39065338-F475D1DE-1DBE-42E1-AC1E-0EC42418CD47Q39932359-600441E1-E71D-458B-AFED-317E71BB8EF9Q39965433-174278DC-A12E-46FA-A6BE-4B138FFDB4E5Q40763424-1CC293FF-812B-42B1-A654-D4AE02944E87Q40777711-FAEF2524-D36A-479D-A676-2409C8F143F7Q40784890-1A8D7FC5-5AE4-4EB5-8A48-D7D1792E97C5Q40865045-932000AB-FE0E-4CCC-AABA-46D78DDF94E7Q41559216-C9D7E084-E6C8-4D87-84F8-5B39967FAB91Q41626627-4D067365-7FB6-4424-9F77-B4B623E91244Q41644519-D8259926-F78E-42AB-A982-5D695F865EFAQ42198842-AA1E5C8A-ED4C-4F80-B1D7-D441B36E5D82Q42200366-7628C194-A226-45EC-82BC-C06527D4E91AQ42233102-85EFF53C-9090-4E29-8A1A-32843D111976Q42245422-C4E13762-3050-4CE3-800F-3EBD27CC4370Q43661889-1CA7E517-4857-40F2-A900-6D947892CCBEQ44250503-FFB7BEF0-E2E3-4077-A186-DC979B0E1A9EQ46696878-85C3D088-C2F3-4B1D-9CEE-3F188DEBE602Q53417515-21B8FB38-F2DD-45AC-A926-8B1560CBCDF3Q54206847-2961982D-F88E-454A-BC50-5E8D715BE45EQ88599116-EDB9CD87-2313-45D9-9FE7-C0DD6B00D8A5Q89186290-DAC1F381-6830-4674-8B9D-26095EBBD7F6Q90060910-5418B63A-ACD1-4770-9580-4AB9A5C2C4F7Q90076177-BF40E448-FE2B-4E8C-AEBC-06DBEC619C85Q90308213-5F1E8A0E-77B4-4370-8144-18B2CF21352AQ91393624-20C8FFB7-8966-4CB0-B8F3-F54C7BA8D9D2Q91418630-31C75A2A-BA2A-4296-A28D-818DE4A458E6Q91860574-BC89CA6C-8DA5-47A6-BB12-9C0E6169DF4AQ92012543-857F124E-9F35-4F46-AB4D-A766967A7BD4Q92310881-7523A249-867D-4B15-A15F-70144F37D99EQ92340288-883AB080-54CB-4623-A6B4-B35EF19D2F9AQ92947962-A5767CED-E96F-48B6-834A-FF0E41BF6EB0
P50
description
investigador
@es
researcher
@en
name
J L Casado
@en
type
label
J L Casado
@en
prefLabel
J L Casado
@en
P31
P496
0000-0002-7639-8591